# US 11,299,534 B2 · CD8A-binding fibronectin type III domains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,534 B2
- Document ID: US11299534B2
- Status: Granted
- Kind: B2
- Application number: 16/821,064
- Filed: 2020-03-17
- Published: 2021-02-04
- Granted: 2022-04-12
- Earliest claimed: 2016-12-14
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Rebecca Hawkins; Steven Jacobs; Manuel Sepulveda
- Web page: https://patentgrep.com/patent/US11299534B2

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/56966: {Animal cells}
- G01N 33/575: for cancer
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/70517: CD8
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.

## Claims

### Claim 1

A protein comprising the amino acid sequence of SEQ ID NO 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, or SEQ ID NO: 234.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the protein comprises the amino acid of SEQ ID NO: 229.

### Claim 3 (depends on 1)

The protein of claim 1, wherein the protein comprises the amino acid of SEQ ID NO: 230.

### Claim 4 (depends on 1)

The protein of claim 1, wherein the protein is conjugated to a second molecule.

### Claim 5 (depends on 1)

The protein of claim 1, wherein the protein comprises the amino acid of SEQ ID NO: 231.

### Claim 6 (depends on 1)

The protein of claim 1, further comprising a methionine at the N-terminus of the protein.

### Claim 7 (depends on 1)

The protein of claim 1, wherein the protein is coupled to a half-life extending moiety.

### Claim 8 (depends on 7)

The protein of claim 7, wherein the half-life extending moiety is albumin, an albumin binding molecule, a polyethylene glycol (PEG), or an Fe region of an immunoglobulin.

### Claim 9 (depends on 1)

A capture agent comprising the protein of claim 1.

### Claim 10 (depends on 4)

The protein of claim 4, wherein the second molecule is a detectable label.

### Claim 11 (depends on 10)

The protein of claim 10, wherein the detectable label is selected from a group consisting of radioactive isotope, magnetic beads, metallic beads, colloidal particles, a fluorescent dye, an electron-dense reagent, an enzyme, biotin, digoxigenin, and hapten.

### Claim 12 (depends on 4)

The protein of claim 4, wherein the second molecule is a cytotoxic agent.

### Claim 13 (depends on 4)

The protein of claim 4, wherein the second molecule is a chelator.

### Claim 14 (depends on 4)

The protein of claim 4, wherein the second molecule is a nucleic acid molecule.

### Claim 15 (depends on 1)

The protein of claim 1, wherein the protein comprises the amino acid of SEQ ID NO: 232.

### Claim 16 (depends on 1)

The protein of claim 1, wherein the protein comprises the amino acid of SEQ ID NO: 234.

### Claim 17 (depends on 1)

A composition comprising the protein of claim 1.

### Claim 18 (depends on 12)

A composition comprising the protein of claim 12.

### Claim 19 (depends on 13)

A composition comprising the protein of claim 13.

### Claim 20 (depends on 14)

A composition comprising the protein of claim 14.